206 related articles for article (PubMed ID: 30836026)
1. Efficacy of topical imiquimod 3.75% in the treatment of actinic keratosis of the scalp in immunosuppressed patients: our case series.
Zavattaro E; Veronese F; Landucci G; Tarantino V; Savoia P
J Dermatolog Treat; 2020 May; 31(3):285-289. PubMed ID: 30836026
[No Abstract] [Full Text] [Related]
2. Physician-patient communication and patient-reported outcomes in the actinic keratosis treatment adherence initiative (AK-TRAIN): a multicenter, prospective, real-life study of treatment satisfaction, quality of life and adherence to topical field-directed therapy for the treatment of actinic keratosis in Italy.
Neri L; Peris K; Longo C; Calvieri S; Frascione P; Parodi A; Eibenschuz L; Bottoni U; Pellacani G;
J Eur Acad Dermatol Venereol; 2019 Jan; 33(1):93-107. PubMed ID: 29920789
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of imiquimod 3.75% from Lmax according to the number of actinic keratosis lesions.
Peris K; Stockfleth E; Gupta G; Aractingi S; Dakovic R; Dirschka T; Alomar A
J Eur Acad Dermatol Venereol; 2015 Dec; 29(12):2470-3. PubMed ID: 25351284
[TBL] [Abstract][Full Text] [Related]
4. Long-term sustained lesion clearance from Lmax with imiquimod 3.75%, a new field-directed treatment for actinic keratosis.
Gupta G; Stockfleth E; Peris K; Aractingi S; Alomar A; Dakovic R; Dirschka T
J Eur Acad Dermatol Venereol; 2015 Sep; 29(9):1840-2. PubMed ID: 25174261
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety of Imiquimod 3.75% from Lmax in Actinic Keratosis According to Fitzpatrick Skin Type.
Alomar A; Stockfleth E; Dirschka T; Gupta G; Aractingi S; Dakovic R; Peris K
J Drugs Dermatol; 2016 Mar; 15(3):285-9. PubMed ID: 26954313
[TBL] [Abstract][Full Text] [Related]
6. Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: two phase 3 multicenter, randomized, double-blind, placebo-controlled studies.
Swanson N; Smith CC; Kaur M; Goldenberg G
J Drugs Dermatol; 2013 Nov; 12(11):1278-82. PubMed ID: 24196337
[TBL] [Abstract][Full Text] [Related]
7. Imiquimod 3.75% for field-directed therapy of actinic keratosis: results of a prospective case-series study in Greece.
Befon A; Tzanetakou V; Panagiotopoulos A; Chasapi V; Antoniou C; Stratigos AJ
Int J Dermatol; 2019 Sep; 58(9):1040-1044. PubMed ID: 30779341
[TBL] [Abstract][Full Text] [Related]
8. Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: two phase 3, multicenter, randomized, double-blind, placebo-controlled studies.
Swanson N; Smith CC; Kaur M; Goldenberg G
J Drugs Dermatol; 2014 Feb; 13(2):166-9. PubMed ID: 24509967
[TBL] [Abstract][Full Text] [Related]
9. Clinical experience of imiquimod 3.75% for actinic keratosis: results from a case series.
Tambone S; Fargnoli MC; Capizzi R; Peris K
G Ital Dermatol Venereol; 2018 Jun; 153(3):333-337. PubMed ID: 26439591
[TBL] [Abstract][Full Text] [Related]
10. Lmax and imiquimod 3.75%: the new standard in AK management.
Stockfleth E
J Eur Acad Dermatol Venereol; 2015 Jan; 29 Suppl 1():9-14. PubMed ID: 25470719
[TBL] [Abstract][Full Text] [Related]
11. Reduction in lesions from Lmax: a new concept for assessing efficacy of field-directed therapy for actinic keratosis. Results with imiquimod 3.75%.
Stockfleth E; Gupta G; Peris K; Aractingi S; Dakovic R; Alomar A
Eur J Dermatol; 2014; 24(1):23-7. PubMed ID: 24589500
[TBL] [Abstract][Full Text] [Related]
12. Increased number of mast cells in the dermis in actinic keratosis lesions effectively treated with imiquimod.
Oyama S; Funasaka Y; Tsuchiya SI; Kawana S; Saeki H
J Dermatol; 2017 Aug; 44(8):944-949. PubMed ID: 28342266
[TBL] [Abstract][Full Text] [Related]
13. Two cases of erosive pustular dermatosis of the scalp occurring after topical 3.75% imiquimod for actinic keratoses.
Giuffrida R; Borgia F; Cannavò SP
Dermatol Ther; 2019 Jan; 32(1):e12770. PubMed ID: 30315627
[No Abstract] [Full Text] [Related]
14. Photodynamic therapy is more effective than imiquimod for actinic keratosis in organ transplant recipients: a randomized intraindividual controlled trial.
Togsverd-Bo K; Halldin C; Sandberg C; Gonzalez H; Wennberg AM; Sørensen SS; Wulf HC; Haedersdal M
Br J Dermatol; 2018 Apr; 178(4):903-909. PubMed ID: 28796885
[TBL] [Abstract][Full Text] [Related]
15. Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: results of two placebo-controlled studies of daily application to the face and balding scalp for two 2-week cycles.
Swanson N; Abramovits W; Berman B; Kulp J; Rigel DS; Levy S
J Am Acad Dermatol; 2010 Apr; 62(4):582-90. PubMed ID: 20133013
[TBL] [Abstract][Full Text] [Related]
16. Topical immunomodulation under systemic immunosuppression: results of a multicentre, randomized, placebo-controlled safety and efficacy study of imiquimod 5% cream for the treatment of actinic keratoses in kidney, heart, and liver transplant patients.
Ulrich C; Bichel J; Euvrard S; Guidi B; Proby CM; van de Kerkhof PC; Amerio P; Rønnevig J; Slade HB; Stockfleth E
Br J Dermatol; 2007 Dec; 157 Suppl 2(Suppl 2):25-31. PubMed ID: 18067628
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of imiquimod 3.75% cream applied daily for 3 weeks to actinic keratoses on the face and/or balding scalp.
Kulp J; Levy S; Fein MC; Adams M; Furst J; Meng TC
Arch Dermatol Res; 2010 Sep; 302(7):539-44. PubMed ID: 20204654
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of a film-forming medical device containing sunscreen (50+) and piroxicam 0.8% in actinic keratosis and field cancerization: a multicenter, assessor-blinded, 3 month trial.
Puviani M; Galloni C; Marchetti S; Sergio Pavone P; Lovati S; Pistone G; Caputo V; Tilotta G; Scarcella G; Campione E; Diluvio L; Garofalo V; Bianchi L; Milani M
Curr Med Res Opin; 2017 Jul; 33(7):1255-1259. PubMed ID: 28358282
[TBL] [Abstract][Full Text] [Related]
19. Long-term clinical outcomes of imiquimod 5% cream vs. diclofenac 3% gel for actinic keratosis on the face or scalp: a pooled analysis of two randomized controlled trials.
Gollnick H; Dirschka T; Ostendorf R; Kerl H; Kunstfeld R
J Eur Acad Dermatol Venereol; 2020 Jan; 34(1):82-89. PubMed ID: 31407414
[TBL] [Abstract][Full Text] [Related]
20. Results of a randomized, placebo-controlled safety and efficacy study of topical diclofenac 3% gel in organ transplant patients with multiple actinic keratoses.
Ulrich C; Johannsen A; Röwert-Huber J; Ulrich M; Sterry W; Stockfleth E
Eur J Dermatol; 2010; 20(4):482-8. PubMed ID: 20507841
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
